Skip to main content

Table 1 Characteristics of locally advanced ESCC patients

From: Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study

Characteristics

ESCC patients (N = 16)

Age (years)

 Median (IQR)

60.5 (56.0-67.3)

 Mean±SD

60.9±7.8

Male, No. (%)

14 (87.5)

ECOG PS, no. (%)

 0

13 (81.3)

 1

3 (18.8)

Tumor location, no. (%)

 Proximal third

3 (18.8)

 Middle third

8 (50.0)

 Distal third

5 (31.3)

Histological grade, no. (%)

 Well

1 (6.3)

  Moderate

8 (50.0)

  Poor

7 (43.7)

Clinical T stage, no. (%)

 cT1

0 (0.0)

 cT2

2 (12.5)

 cT3

13 (81.3)

 cT4

1 (6.3)

Clinical N stage, no. (%)

 N0

2 (12.5)

 N1

10 (62.5)

 N2

3 (18.8)

 N3

1 (6.3)

Clinical TNM stage, no. (%)

 Stage I

0 (0.0)

 Stage II

4 (25.0)

 Stage III

10 (62.5)

 Stage IV

2 (12.5)

  1. ESCC esophageal squamous cell carcinoma, IQR interquartile range, SD standard deviation, ECOG PS Eastern Cooperative Oncology Group performance status